Quotient Clinical Acquires Co-Formulate Limited

Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-01-06-2016
Volume 12
Issue 1

Quotient Clinical announced on Dec. 16, 2015 that is has acquired Co-Formulate Limited.

On Dec. 16, 2015 Quotient Clinical announced that it has acquired contract development company Co-Formulate Limited.

Quotient Clinical is a drug-development services company. The company created a Translational Pharmaceutics platform, which integrates formulation development, GMP manufacturing, and clinical testing. Co-Formulate Limited is a contract product development company that provides a range of comprehensive development, analytical, and regulatory services.

Quotient Clinical’s acquisition of Co-Formulate extends Quotient’s existing pharmaceutical development capabilities across solid, semisolid and liquid formulations. Co-Formulate is based adjacent to Quotient’s new GMP facility in Nottingham, UK, which will enable integration of formulation development and GMP manufacturing services. 

Financial terms of the transaction were not disclosed. 

Source: Quotient Clinical

 

Recent Videos
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content